US$ 22.43
is retatrutide a glp 1 drug Retatrutide, GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA What GLP‑3 Really Is: Retatrutide
Description
At that point, if theyd like to proceed with the GLP1 and they meet criteria, then we roll with it and we consider it harm reduction

Seventy-four participants in each cohort were excluded for having a pre-existing diagnosis of heart failure
Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, Beuschlein F, Puhan MA, Yebyo HG

80% of patients at that point were still on the drug, a self-described impressive retention rate suggesting very good tolerability